Merck ENFLONSIA sBLA Accepted: FDA Will Review RSV Protection for Kids Under 2

The FDA accepted Merck’s (MRK) supplemental Biologics License Application for ENFLONSIA on August 6, seeking to expand the RSV monoclonal antibody’s indication to children under 2 years old at increased risk for severe RSV disease. Merck shares closed at $128.33 on August 5, with a market cap of roughly $325 billion.

ENFLONSIA (clesrovimab-cfor) is already approved for infants during their first RSV season, with FDA authorization in June 2025 and European Commission approval in April 2026. This sBLA extends the label into a smaller but higher-acuity group: children with chronic lung disease, congenital heart disease, or prematurity who remain vulnerable through their second RSV season.

The SMART trial provided the supporting evidence. Antibody concentrations in high-risk children under 2 who received a second-season dose of ENFLONSIA were comparable to levels in healthy infants from the registrational CLEVER trial. The data support a strategy of annual monoclonal antibody dosing through the second RSV season for children who do not outgrow their risk after infancy. Merck has not yet disclosed the PDUFA goal date for the sBLA.

The RSV prevention field has become one of biopharma’s fastest-growing markets. Sanofi and AstraZeneca’s Beyfortus (nirsevimab) was the first infant RSV monoclonal antibody approved and generated over $2 billion in 2025. Merck is building ENFLONSIA into a franchise that reaches from newborns through second-season high-risk children, while also developing an adult RSV vaccine program. The RSV market is increasingly crowded, with GSK, Moderna, and Pfizer all competing in the adult vaccine segment and Sanofi holding the infant antibody lead.

The pediatric RSV antibody market is driven by the 2023-24 CDC universal recommendation for infant RSV protection, which made seasonal RSV immunoprophylaxis standard of care for all infants. The recommendation transformed the market from a niche pediatric subspecialty product to a universal infant health measure, driving the multibillion-dollar commercial opportunity. Expanding into the second RSV season captures the patients who age out of first-season coverage but remain clinically vulnerable, a population that previously had no approved prophylaxis option beyond the older and less convenient Synagis (palivizumab), which required monthly injections throughout the RSV season.

What to watch next: the PDUFA date. Once the FDA sets the review clock, the timeline will determine whether ENFLONSIA’s expanded label is available for the 2026-27 RSV season or slips into 2027. A Priority Review designation would put it on a six-month track; standard review is ten months. Merck has not indicated whether it requested priority review for this filing.

What It Means for the Trade

At a $325 billion market cap, an sBLA acceptance in pediatric RSV is a rounding error for Merck’s stock — this is not a reason to buy MRK, and the shares did not move on it. What it is, is quiet franchise construction. ENFLONSIA launched into its first RSV season against an entrenched incumbent in Beyfortus, and every label expansion — second-season high-risk children now, an adult vaccine program behind it — widens the revenue funnel without requiring a new molecule. RSV prevention is one of the few vaccine-adjacent markets still posting genuine growth, powered by the universal infant recommendation that converted prophylaxis from a subspecialty product into standard of care.

The commercial subtext is the competitive one. Sanofi and AstraZeneca split Beyfortus’s $2-billion-plus franchise, and the second-season high-risk population is one of the few pediatric niches Beyfortus has not locked down. If ENFLONSIA wins this label, Merck can pitch the high-risk track as its own — the kids who age out of first-season coverage but stay vulnerable. It is a smaller, higher-acuity slice, but it is also a population where payers are least price-sensitive.

Mechanism and Market Context

Clesrovimab is a long-acting anti-RSV monoclonal antibody targeting the fusion protein, dosed once per season. The sBLA’s evidence package is pharmacokinetic bridging, not a new efficacy trial: SMART showed that antibody concentrations in high-risk children under two receiving a second-season dose were comparable to levels in healthy infants from the registrational CLEVER trial. That is a standard extrapolation playbook for mAb label expansions and the FDA accepts it routinely — but it also means the filing carries no new clinical-outcome data, so any safety question in this sicker population would land on a thinner evidentiary base.

The clinical logic is sound. Children with chronic lung disease, congenital heart disease, or extreme prematurity remain at elevated risk through their second RSV season — the exact population Synagis covered for decades with monthly injections. A single-dose alternative to monthly Synagis is an obvious convenience win for pediatricians and payers alike, and the comparator economics favor it if pricing lands near Beyfortus’s.

Risks and What Could Go Wrong

1. Review timeline slip. No PDUFA date disclosed yet; a standard ten-month review pushes availability into the 2027-28 season, delaying revenue a full year.
2. ACIP and coding. An expanded label does not guarantee a recommendation or favorable immunization scheduling for the second-season population; without ACIP language, uptake will be payer-by-payer and slow.
3. Pricing pressure. Beyfortus dominates procurement conversations, and a niche label expansion has little leverage to command premium pricing.
4. Competitive response. Sanofi and AstraZeneca can pursue the same population with their own filings; first label wins the niche.

For the stock, this is a nothing-burger in the near term. For the ENFLONSIA franchise trajectory, it is one more tile in a growing mosaic — worth tracking, not worth trading.